{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+of+care+systemic+therapy&page=3", "query": { "intervention": "Standard of care systemic therapy", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 240, "total_pages": 24, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+of+care+systemic+therapy&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+of+care+systemic+therapy&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T00:09:04.350Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02652572", "title": "Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Venous Leg Ulcers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Venous Leg Ulcer" ], "interventions": [ { "name": "Granexin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Xequel Bio, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2015-09", "completion_date": "2018-05", "has_results": false, "last_update_posted_date": "2018-08-01", "last_synced_at": "2026-10-05T00:09:04.350Z", "location_count": 3, "location_summary": "Augusta, Georgia • Spartanburg, South Carolina • Salem, Virginia", "locations": [ { "city": "Augusta", "state": "Georgia" }, { "city": "Spartanburg", "state": "South Carolina" }, { "city": "Salem", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02652572" }, { "nct_id": "NCT05169957", "title": "Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma, Ocular", "Melanoma, Cutaneous", "Metastatic Melanoma", "Melanoma, Mucosal", "Liver Metastases" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Stereotactic Body Radiation Therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2022-08-09", "completion_date": "2024-07-17", "has_results": false, "last_update_posted_date": "2024-11-05", "last_synced_at": "2026-10-05T00:09:04.350Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05169957" }, { "nct_id": "NCT07438496", "title": "A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lupus Erythematosus, Systemic" ], "interventions": [ { "name": "Nipocalimab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Standard of care treatment", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 600, "start_date": "2026-03-05", "completion_date": "2031-11-07", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-05T00:09:04.350Z", "location_count": 38, "location_summary": "Beverly Hills, California • Fullerton, California • Hemet, California + 33 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Hemet", "state": "California" }, { "city": "La Palma", "state": "California" }, { "city": "San Leandro", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07438496" }, { "nct_id": "NCT06561048", "title": "Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Peripheral T-Cell Lymphoma, Not Otherwise Specified", "Angioimmunoblastic T-cell Lymphoma", "Follicular T-Cell Lymphoma", "Nodal Peripheral T-Cell Lymphoma With TFH Phenotype", "Systemic Anaplastic Large Cell Lymphoma", "Lymphoma, T-Cell, Peripheral", "Lymphoma, T-Cell" ], "interventions": [ { "name": "Soquelitinib", "type": "DRUG" }, { "name": "Belinostat", "type": "DRUG" }, { "name": "Pralatrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corvus Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2024-10-02", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-05T00:09:04.350Z", "location_count": 24, "location_summary": "Duarte, California • Irvine, California • San Francisco, California + 19 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06561048" }, { "nct_id": "NCT03250832", "title": "Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "TSR-033", "type": "DRUG" }, { "name": "Dostarlimab", "type": "DRUG" }, { "name": "mFOLFOX6", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tesaro, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2017-08-08", "completion_date": "2023-02-13", "has_results": true, "last_update_posted_date": "2024-04-11", "last_synced_at": "2026-10-05T00:09:04.350Z", "location_count": 11, "location_summary": "Los Angeles, California • Whittier, California • Sarasota, Florida + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03250832" }, { "nct_id": "NCT01625845", "title": "Anti-INFLammatory to Address Mood and Endothelial Dysfunction (INFLAMED)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Major Depressive Disorder", "Depression", "Depressive Symptoms", "Cardiovascular Disease (CVD)", "Coronary Artery Disease (CAD)", "Heart Disease" ], "interventions": [ { "name": "Pentoxifylline", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Standard Treatment", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "OTHER", "BEHAVIORAL" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 36, "start_date": "2012-06", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2015-12-03", "last_synced_at": "2026-10-05T00:09:04.350Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01625845" }, { "nct_id": "NCT02119156", "title": "Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "Belimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2014-05-13", "completion_date": "2018-12-14", "has_results": true, "last_update_posted_date": "2020-01-31", "last_synced_at": "2026-10-05T00:09:04.350Z", "location_count": 3, "location_summary": "Los Angeles, California • Manhasset, New York • Dallas, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Manhasset", "state": "New York" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02119156" }, { "nct_id": "NCT02162472", "title": "Videocapillaroscopy Assessment During Systemic Agent Therapy in Psoriasis", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Psoriasis" ], "interventions": [], "intervention_types": [], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 19, "start_date": "2015-07", "completion_date": "2021-12-31", "has_results": false, "last_update_posted_date": "2022-01-11", "last_synced_at": "2026-10-05T00:09:04.350Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02162472" }, { "nct_id": "NCT06436157", "title": "A Pilot Study of Genetic Testing Uptake Through Enhanced Oncology Nurse-Led Intervention", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "Enhanced education", "type": "OTHER" }, { "name": "Usual care education", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2024-12-26", "completion_date": "2025-09-26", "has_results": false, "last_update_posted_date": "2025-01-31", "last_synced_at": "2026-10-05T00:09:04.350Z", "location_count": 2, "location_summary": "Chico, California • Sacramento, California", "locations": [ { "city": "Chico", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06436157" }, { "nct_id": "NCT04662632", "title": "Abbreviated Protocol for Two-Stage Exchange", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prosthetic Joint Infection" ], "interventions": [ { "name": "VT-X7 Treatment System with Tobramycin Sulfate", "type": "COMBINATION_PRODUCT" }, { "name": "Standard of Care", "type": "DRUG" }, { "name": "Two-stage exchange arthroplasty", "type": "PROCEDURE" }, { "name": "VT-X7 Treatment System with Vancomycin Hydrochloride", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DRUG", "PROCEDURE" ], "sponsor": "Osteal Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": "84 Years", "sex": "ALL", "summary": "22 Years to 84 Years" }, "enrollment_count": 76, "start_date": "2021-11-01", "completion_date": "2023-12-22", "has_results": true, "last_update_posted_date": "2026-04-21", "last_synced_at": "2026-10-05T00:09:04.350Z", "location_count": 17, "location_summary": "Phoenix, Arizona • Torrance, California • Washington D.C., District of Columbia + 13 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Torrance", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Weston", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04662632" } ] }